Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Secarna Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Secarna Pharmaceuticals Enters into Cooperation with Guangzhou’s Sun Yat-sen University to Develop a Treatment for SARS-CoV-2

              Contact the Supplier

              Lead Product(s): Antisense oligonucleotides

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sun Yat-sen University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 28, 2020

              Details:

              Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

              Ethris

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Neurimmune and Ethris Enter Collaboration to Rapidly Develop Inhaled mRNA-based Antibody Therapy for COVID-19

              Contact the Supplier

              Lead Product(s): NI007

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Neurimmune

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 01, 2020

              Details:

              Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.

              PharmaCompass__DigitalAd